Antibe Announces Appointment of Receiver

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) was heard before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024 and the decision was reserved.

On April 22, 2024, the Court issued its decision terminating CCAA proceedings and appointing FTI Consulting Canada Inc. as receiver of Antibe.

The Company also announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe’s Board of Directors. In addition, the Company today received notification from the TSX that it will be delisting Antibe’s common shares from the TSX effective as of May 24, 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424042966/en/

Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-577-1443
[email protected]

Source: Antibe Therapeutics Inc.

You May Also Be Interested In

• One Year Later: FHLBank Chicago’s $2 Million AHP Grant Helps Deliver 40 New Homes in Rural Wisconsin
• IP Services Announces Expanded Focus on Executive Cybersecurity and AI Governance Under Scott Alldridge
• Meta Is Back in the AI Race. Muse Wonder Just Ranked #2 for Accounting, According to DualEntry Accounting AI Benchmark